{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:22:17Z","timestamp":1781223737176,"version":"3.54.1"},"reference-count":72,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Breast implant\u2013associated anaplastic large cell lymphoma (BIA-ALCL) is a rare subtype of T-cell non-Hodgkin lymphoma that is usually localized to the fluid and capsule surrounding a breast implant. There have only been &lt;1,000 cases and 36 deaths reported to date and the average patient presents 7 to 10 years following initial breast implant placement. Most patients present with delayed seromas, a breast mass, capsular abnormalities, lymphadenopathy, or cutaneous masses. Unlike other forms of non-Hodgkin lymphoma, most cases are cured with surgery alone. The challenge of BIA-ALCL surrounds its rarity\u2014in regard to both its diagnosis as well as the limited available data to guide therapy for more advanced cases. Careful pathology evaluation to analyze both the fluid surrounding the capsule and the capsule itself is critical. Studies to identify which patients are at greater risk of development of this rare entity are ongoing.<\/jats:p>","DOI":"10.6004\/jnccn.2022.7004","type":"journal-article","created":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T16:27:52Z","timestamp":1647016072000},"page":"309-315","source":"Crossref","is-referenced-by-count":11,"title":["An Updated Approach and Understanding of Breast Implant\u2013Associated Anaplastic Large Cell Lymphoma"],"prefix":"10.6004","volume":"20","author":[{"given":"Neha","family":"Mehta-Shah","sequence":"first","affiliation":[{"name":"1Division of Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ghione","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/PRS.0000000000001033","article-title":"Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases","volume":"135","author":"Brody","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jamasurg.2019.3154","article-title":"Breast implant-associated anaplastic large cell lymphoma: real, rare, but avoidable","volume":"155","author":"Myckatyn","year":"2020","journal-title":"JAMA Surg"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/asj\/sjy331","article-title":"2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)","volume":"39","author":"Clemens","year":"2019","journal-title":"Aesthet Surg J"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1055-9965.EPI-13-0633","article-title":"Breast implants and anaplastic large-cell lymphoma: a danish population-based cohort study","volume":"22","author":"Vase","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.19.02778","article-title":"Best practices guideline for the pathologic diagnosis of breast implant-associated anaplastic large-cell lymphoma","volume":"38","author":"Jaffe","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"e0181097","DOI":"10.1371\/journal.pone.0181097","article-title":"Cytological diagnostic features of late breast implant seromas: from reactive to anaplastic large cell lymphoma","volume":"12","author":"Di Napoli","year":"2017","journal-title":"PLoS One"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/PRS.0000000000003654","article-title":"Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk","volume":"140","author":"Loch-Wilkinson","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/tbj.14205","article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway","volume":"27","author":"Quesada","year":"2021","journal-title":"Breast J"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/asj\/sjw259","article-title":"NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma","volume":"37","author":"Clemens","year":"2017","journal-title":"Aesthet Surg J"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1097\/PRS.0000000000005571","article-title":"Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): initial report of findings, 2012\u20132018","volume":"143","author":"McCarthy","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2008.585","article-title":"Anaplastic large-cell lymphoma in women with breast implants","volume":"300","author":"de Jong","year":"2008","journal-title":"JAMA"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.2019004498","article-title":"Increased prevalence of BRCA1\/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast","volume":"136","author":"de Boer","year":"2020","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"65S","DOI":"10.1097\/PRS.0000000000005571","article-title":"Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma Etiology and Epidemiology (PROFILE): initial report of findings, 2012\u20132018","volume":"143","author":"McCarthy","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1097\/HS9.0000000000000501","article-title":"The successful use of neo adjuvant brentuximab vedotin in the treatment of BIA-ALCL","volume":"4","author":"Allchin","year":"2020","journal-title":"HemaSphere"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41379-018-0134-3","article-title":"Breast implant-associated anaplastic large cell lymphoma: a review","volume":"32","author":"Quesada","year":"2019","journal-title":"Mod Pathol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1001\/jama.2008.585","article-title":"Anaplastic large-cell lymphoma in women with breast implants","volume":"300","author":"de Jong","year":"2008","journal-title":"JAMA"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1158\/1055-9965.EPI-13-0633","article-title":"Breast implants and anaplastic large-cell lymphoma: a danish population-based cohort study","volume":"22","author":"Vase","year":"2013","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2017.4510","article-title":"Breast implants and the risk of anaplastic large-cell lymphoma in the breast","volume":"4","author":"de Boer","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/asj\/sjz377","article-title":"A cautionary tale and update on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)","volume":"40","author":"Ghosh","year":"2020","journal-title":"Aesthet Surg J"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PRS.0000000000002837","article-title":"Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving Natrelle 410 form-stable silicone breast implants","volume":"139","author":"McGuire","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"ref541","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.1565","article-title":"Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants [abstract]","volume":"37","author":"Ghione","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1097\/PRS.0000000000005568","article-title":"Characteristics and treatment of advanced breast implant-associated anaplastic large cell lymphoma","volume":"143","author":"Collins","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ccr3.1382","article-title":"Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma","volume":"6","author":"Alderuccio","year":"2018","journal-title":"Clin Case Rep"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/tbj.14205","article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway","volume":"27","author":"Quesada","year":"2021","journal-title":"Breast J"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1097\/HS9.0000000000000501","article-title":"The successful use of neo adjuvant brentuximab vedotin in the treatment of BIA-ALCL","volume":"4","author":"Allchin","year":"2020","journal-title":"HemaSphere"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"101963","DOI":"10.1016\/j.ctrv.2020.101963","article-title":"Breast implant-associated anaplastic large cell lymphoma: a comprehensive review","volume":"84","author":"Marra","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.14431","article-title":"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK\/STAT signalling pathway genes, TP53 and DNMT3A","volume":"180","author":"Di Napoli","year":"2018","journal-title":"Br J Haematol"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/PRS.0000000000003282","article-title":"U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma","volume":"139","author":"Doren","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/annonc\/mdv575","article-title":"Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes","volume":"27","author":"Laurent","year":"2016","journal-title":"Ann Oncol"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1182\/blood.2019004498","article-title":"Increased prevalence of BRCA1\/2 mutations in women with macrotextured breast implants and anaplastic large cell lymphoma of the breast","volume":"136","author":"de Boer","year":"2020","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"e0181097","DOI":"10.1371\/journal.pone.0181097","article-title":"Cytological diagnostic features of late breast implant seromas: from reactive to anaplastic large cell lymphoma","volume":"12","author":"Di Napoli","year":"2017","journal-title":"PLoS One"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"169","DOI":"10.21037\/gs.2016.11.03","article-title":"Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules","volume":"6","author":"Clemens","year":"2017","journal-title":"Gland Surg"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"41S","DOI":"10.1097\/PRS.0000000000005568","article-title":"Characteristics and treatment of advanced breast implant-associated anaplastic large cell lymphoma","volume":"143","author":"Collins","year":"2019","journal-title":"Plast Reconstr Surg"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","article-title":"Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma","volume":"34","author":"Clemens","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41379-018-0134-3","article-title":"Breast implant-associated anaplastic large cell lymphoma: a review","volume":"32","author":"Quesada","year":"2019","journal-title":"Mod Pathol"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00266-019-01521-3","article-title":"Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and the textured breast implant crisis","volume":"44","author":"Groth","year":"2020","journal-title":"Aesthetic Plast Surg"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref131","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.1565","article-title":"Risk of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3,546 women prospectively followed after receiving textured breast implants [abstract]","volume":"37","author":"Ghione","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/PRS.0000000000002837","article-title":"Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving Natrelle 410 form-stable silicone breast implants","volume":"139","author":"McGuire","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"ref791","first-page":"360","article-title":"Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL","volume":"135","author":"Laurent","year":"2020","journal-title":"Blood"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoncol.2017.4510","article-title":"Breast implants and the risk of anaplastic large-cell lymphoma in the breast","volume":"4","author":"de Boer","year":"2018","journal-title":"JAMA Oncol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00266-019-01521-3","article-title":"Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and the textured breast implant crisis","volume":"44","author":"Groth","year":"2020","journal-title":"Aesthetic Plast Surg"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/ccr3.1382","article-title":"Frontline brentuximab vedotin in breast implant-associated anaplastic large-cell lymphoma","volume":"6","author":"Alderuccio","year":"2018","journal-title":"Clin Case Rep"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/asj\/sju084","article-title":"Ten-year results from the Natrelle 410 anatomical form-stable silicone breast implant core study","volume":"35","author":"Maxwell","year":"2015","journal-title":"Aesthet Surg J"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"101963","DOI":"10.1016\/j.ctrv.2020.101963","article-title":"Breast implant-associated anaplastic large cell lymphoma: a comprehensive review","volume":"84","author":"Marra","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1200\/JCO.19.02778","article-title":"Best practices guideline for the pathologic diagnosis of breast implant-associated anaplastic large-cell lymphoma","volume":"38","author":"Jaffe","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3892\/mco.2017.1170","article-title":"Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: a case report and review of the literature","volume":"6","author":"Richardson","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2013.52.7911","article-title":"Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients","volume":"32","author":"Miranda","year":"2014","journal-title":"J Clin Oncol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.3324\/haematol.2016.146118","article-title":"Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma","volume":"101","author":"Blombery","year":"2016","journal-title":"Haematologica"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1097\/PRS.0000000000001033","article-title":"Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases","volume":"135","author":"Brody","year":"2015","journal-title":"Plast Reconstr Surg"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamasurg.2017.4026","article-title":"Breast implant-associated anaplastic large cell lymphoma: a systematic review","volume":"152","author":"Leberfinger","year":"2017","journal-title":"JAMA Surg"},{"key":"ref381","first-page":"360","article-title":"Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL","volume":"135","author":"Laurent","year":"2020","journal-title":"Blood"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"169","DOI":"10.21037\/gs.2016.11.03","article-title":"Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules","volume":"6","author":"Clemens","year":"2017","journal-title":"Gland Surg"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/asj\/sju084","article-title":"Ten-year results from the Natrelle 410 anatomical form-stable silicone breast implant core study","volume":"35","author":"Maxwell","year":"2015","journal-title":"Aesthet Surg J"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3892\/mco.2017.1170","article-title":"Breast implant-associated anaplastic large-cell lymphoma and the role of brentuximab vedotin (SGN-35) therapy: a case report and review of the literature","volume":"6","author":"Richardson","year":"2017","journal-title":"Mol Clin Oncol"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1200\/JCO.2015.63.3412","article-title":"Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma","volume":"34","author":"Clemens","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1001\/jamasurg.2019.3154","article-title":"Breast implant-associated anaplastic large cell lymphoma: real, rare, but avoidable","volume":"155","author":"Myckatyn","year":"2020","journal-title":"JAMA Surg"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/bjh.14431","article-title":"Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK\/STAT signalling pathway genes, TP53 and DNMT3A","volume":"180","author":"Di Napoli","year":"2018","journal-title":"Br J Haematol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/asj\/sjy331","article-title":"2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)","volume":"39","author":"Clemens","year":"2019","journal-title":"Aesthet Surg J"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/asj\/sjw259","article-title":"NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma","volume":"37","author":"Clemens","year":"2017","journal-title":"Aesthet Surg J"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/asj\/sjz377","article-title":"A cautionary tale and update on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)","volume":"40","author":"Ghosh","year":"2020","journal-title":"Aesthet Surg J"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/annonc\/mdv575","article-title":"Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes","volume":"27","author":"Laurent","year":"2016","journal-title":"Ann Oncol"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/AJR.09.3665","article-title":"Characterization of T-cell lymphomas by FDG PET\/CT","volume":"195","author":"Feeney","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/PRS.0000000000003654","article-title":"Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk","volume":"140","author":"Loch-Wilkinson","year":"2017","journal-title":"Plast Reconstr Surg"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1001\/jamasurg.2017.4026","article-title":"Breast implant-associated anaplastic large cell lymphoma: a systematic review","volume":"152","author":"Leberfinger","year":"2017","journal-title":"JAMA Surg"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/PRS.0000000000003282","article-title":"U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma","volume":"139","author":"Doren","year":"2017","journal-title":"Plast Reconstr Surg"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/3\/article-p309.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/20\/3\/article-p309.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T18:10:59Z","timestamp":1647022259000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/20\/3\/article-p309.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":72,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2022.7004","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}